Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Born under fire: MDA delivers baby in Jerusalem minutes before rushing to shelter - 2Colorado residents face earliest water restrictions ever — a harbinger of worse to come
- 3'Euphoria' Season 3 trailer includes Eric Dane's final appearance, Jacob Elordi and Sydney Sweeney at the altar and Zendaya's 'Breaking Bad' era
- 4Kids with smartphones by age 12 are at higher risk of health issues, study finds
- 5Doctors looking into hormone therapy as a way to ward off dementia in women
- Why don’t humans have hair all over their bodies? A biologist explains our lack of fur
- Is an $85 apple pie worth it? Our Thanksgiving taste test says … maybe.
- The Eastern Bongo, Kenya’s Rare Forest Antelope on the Brink
- What's Your #1 Pizza Beating Mix?
- NI economy losing momentum due to Iran crisis
- The most effective method to Shield Your Gold Ventures: Procedures and Precautionary measures
- Reality TV star Spencer Pratt, who lost his home in Palisades Fire, is running for mayor of Los Angeles
- Iconic iceberg turns blue, on verge of totally disintegrating, NASA says
- Bennu asteroid samples provide clues about solar system origins and 'space gum'
